Saniona-FPWR unite to raise awareness about Phase 2b Tesomet trial
Category: #health  By Pankaj Singh  Date: 2021-04-20
  • sharesocial_share_icon
  • Twitter
  • Facebook
  • LinkedIn

Saniona-FPWR unite to raise awareness about Phase 2b Tesomet trial

Saniona, a biotechnology operation company, has recently entered a partnership deal with the FPWR (Foundation for Prader-Willi Research). This partnership deal has been inked with an aim to increase awareness about the company’s Phase 2b Tesomet trial within the FPWR’s community. The clinical trial is likely to start in the 1st half of 2021 and examine Tesomet for the treatment of PWS (Prader-Willi syndrome).

According to the CEO of FPWR, John Walter, the recent clinical trial is highly crucial for the PWS community due to the unavailability of approved treatment to manage hyperphagia, a common symptom of PWS. The company is pleased to collaborate with Saniona on the latest program to help patients gain knowledge of the clinical trial process, ensure that their views are represented throughout the trial continuum, as well as raise awareness about Saniona’s clinical study within this community.

Saniona and FPWR are planning to conduct a webinar to answer questions and provide information about the clinical trial, as a part of the latest partnership. In addition, FPWR will leverage its email, online, and social media platforms to increase awareness about the trial.

As per the statement made by Saniona’s Head of Clinical Development and Chief Medical Officer, Rudolf Baumgartner, M.D., the company is excited to unite with FPWR as it prioritizes on incorporating the feedback of caregivers and patients into its clinical trial activities and meeting the needs of the patients with PWS.

The biotechnology operation company has previously conducted a randomized, placebo-controlled, double-blind Phase 2b trial of Tesomet among adolescents and adults suffering from PWS. Adult patients that received the therapy had achieved a clinically meaningful bodyweight reduction and statistically significant hyperphagia reduction at a dose of 0.5 mg in a day. For the record, the company is currently evaluating the therapy to treat HO (hypothalamic obesity).

Source credit:

https://www.globenewswire.com/news-release/2021/04/19/2212312/0/en/Saniona-Announces-Partnership-with-the-Foundation-for-Prader-Willi-Research-FPWR-to-Support-its-Prader-Willi-Syndrome-PWS-Clinical-Trial-with-Tesomet.html



About Author

Pankaj Singh

Email: [email protected]   linkdin twitter

Pankaj Singh

Pankaj Singh Develops content for Market Size Forecasters, Algosonline, and a couple of other platforms. A Post Graduate in Management by qualification, he worked as an underwriter in the UK insurance domain before deciding to switch his field of profession. With exp...

More News By Pankaj Singh

MGMA partners with WhiteSpace Health to unveil MGMA DataDiscovery tool

MGMA partners with WhiteSpace Health to unveil MGMA DataDiscovery tool

By Pankaj Singh

Well-known medical practice management organization, Medical Group Management Association (MGMA) has reportedly joined forces with WhiteSpace Health to release a new medical group analytics tool, MGMA DataDiscovery. Th...

Santex acquires U.S. online retailer Parentgiving for market expansion

Santex acquires U.S. online retailer Parentgiving for market expansion

By Pankaj Singh

Italy-based personal care and incontinence product manufacturer Santex SPA has reportedly acquired Parentgiving Inc., America’s top-rated e-commerce retailer of geriatric care products.

LVMH revamps La Samaritaine store and opens it in tourist-less Paris

LVMH revamps La Samaritaine store and opens it in tourist-less Paris

By Pankaj Singh

La Samaritaine, a historic landmark of 19th century France, has been reportedly revamped as a new destination for dining, all-in-one shopping, and tourism by LVMH, a French luxury conglomerate. The stores&rs...